WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, November 3, 2014

LCT completes patient enrollment in Phase I/IIa trial for Parkinson's disease

PBR Staff WriterPublished 03 November 2014
Australasian biotechnology firm Living Cell Technologies (LCT) has completed patient enrollment in a Phase I/IIa clinical trial of the regenerative cell therapy NTCELL for Parkinson’s disease.


NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.
The open-label trial will evaluate the safety and clinical effects of NTCELL in patients who can no longer respond to the existing therapy.
The capsule is directed by Parkinson's disease clinician and researcher Dr Barry Snow who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board.

LCT chief executive Dr Ken Taylor said: " I congratulate the clinical team at Auckland Hospital for the coordination and interaction with all required regulatory and ethical authorities required to successfully recruit all patients for this innovative clinical study.

"Now we look forward to the clinical study outcome in 2015. We remain excited about the potential for NTCELL to be the first disease modifying treatment for patients who are failing the current conventional treatment for Parkinson's disease."

The company said that NTCELL also has the potential to be used in a number of other central nervous system (CNS) indications such as Huntington's, Alzheimer's and motor neurone diseases.

No comments:

Post a Comment